The outcome of haematopoietic stem cell transplantation in a patient with STAT1 gain-of-function: a case report
Abstract
Background: The human signal transducer and activator of transcription 1 (STAT1) is a latent cytoplasmic transcription factor and one of seven members of the STAT family. Autosomal dominant (AD) STAT1 gain-of-function (GOF), characterized by enhanced phosphorylation of the tyrosine-701 residue and STAT1 activation, is commonly associated with chronic mucocutaneous candidiasis (CMCC), immunodeficiency, aneurysms, malignancies, and autoimmune phenomena.
The best management strategies for patients with STAT1 GOF remain unclear. Typically, the standard care includes supportive treatments such as antimicrobial prophylaxis, either alone or combined with immunoglobulin replacement therapy. Biological therapies such as JAK inhibitors have been shown to alleviate symptoms of infection and autoimmune disorders in patients with STAT1 GOF mutations. However, there is a lack of long-term outcome data for JAK inhibition. Hematopoietic stem cell transplantation (HSCT) is an alternative treatment option for a subset who experience a persistent disease course despite conventional therapy. However, the effectiveness of HSCT for this condition is not yet well established.
Methods: Our patient’s medical records were analyzed retrospectively, including her medical history.
Results: We present the outcome of HSCT performed on a 27-year-old female with STAT1 GOF, conducted as a treatment for acute myeloid leukemia (AML).
Conclusion: HSCT may serve as an alternative and potentially curative treatment for certain STAT1 GOF patients with progressive, life-threatening conditions that do not respond to conventional therapies. Additional research is needed to improve the management of these patients.
Statement of Novelty: We present a novel case study of HSCT as a treatment for AML in a 27-year-old patient with STAT1 GOF, highlighting the potential for curative outcomes in progressive, life-threatening conditions unresponsive to conventional therapies. This case contributes to the limited body of evidence supporting the efficacy and challenges of HSCT in STAT1 GOF patients.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
Al Shehri T., Gilmour K., Gothe F., Loughlin S., Bibi S., Rowan A.D., Grainger A., Mohanadas T., Cant A.J., Slatter M.A., Hambleton S., Lilic D., and Leahy T.R. 2019. Novel gain-of-function mutation in Stat1 sumoylation site leads to CMC/CID phenotype responsive to Ruxolitinib. J. Clin. Immunol. 39(8): 776–785.
Guo L., Lian D., Gu Y., Lu X., Zhang Y., Li X., Khrustaleva T.A., Lan J., Liang Y., Khrustalev V.V., Mao Y., Chen Y., Lu H., and Yuan J. 2024. Dysregulated STAT1 gain-of-function: Pathogen-free autoimmunity and fungal infection. hLife, 2: 397–418.
Henrickson S.E., Dolan J.G., Forbes L.R., Vargas-Hernández A., Nishimura S., Okada S., Kersun L.S., Brodeur G.M., and Heimall J.R. 2019. Gain-of-function STAT1 mutation with familial lymphadenopathy and Hodgkin lymphoma. Front. Pediatrics, 7: 160.
Kaviany S., Bartkowiak T., Dulek D.E., Khan Y.W., Hayes M.J., Schaefer S., Dahunsi D.O., Connelly J.A., Irish J.M., and Rathmell J.C. 2021. STAT1 gain-of-function variants drive altered T cell prevalence, metabolism, and heightened IL-6 sensitivity. bioRxiv.
Kiykim A., Charbonnier L.M., Akcay A., Karakoc-Aydiner E., Ozen A., Ozturk G., Chatila T.A., and Baris S. 2019. Hematopoietic stem cell transplantation in patients with heterozygous STAT1 gain-of-function mutation. J. Clin. Immunol. 39(1): 37–44.
Kıykım A. 2024. STAT1/STAT3 gain of function and mechanisms of immune dysregulation. Turk. J. Immunol. 12(Suppl 1): 47–52.
Leiding J. W., Okada S., Hagin D., Abinun M., Shcherbina A., Balashov D.N., Kim V.H. D., Ovadia A., Guthery S.L., Pulsipher M., Lilic D., Devlin L.A., Christie S., Depner M., Fuchs S., Van Royen-Kerkhof A., Lindemans C., Petrovic A., Sullivan K.E., Bunin N., Kilic S.S., Arpaci F., de la Calle-Martin O., Martinez-Martinez L., Aldave J.C., Kobayashi M., Ohkawa T., Imai K., Iguchi A., Roifman C.M., Gennery A.R., Slatter M., Ochs H. D., Morio T., and Torgerson T.R. 2018. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J. Allergy Clin. Immunol. 141(2): 704–717.
Moriya K., Suzuki T., Uchida N., Nakano T., Katayama S., Irie M., Rikiishi T., Niizuma H., Okada S., Imai K., Sasahara Y., and Kure S. 2020. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation. Int. J. Hematol. 112(2): 258–262.
Okada S., Asano T., Moriya K., Boisson-Dupuis S., Kobayashi M., Casanova J.-L., and Puel A. 2020. Human STAT1 gain-of-function heterozygous mutations: Chronic mucocutaneous candidiasis and type I interferonopathy. J. Clin. Immunol. 40(8): 1065–1081.
Scott O., Dadi H., Vong L., Pasternak Y., Garkaby J., Willett Pachul J., Mandola A.B., Brager R., Hostoffer R., Nahum A., and Roifman C.M. 2022. DNA-Binding domain mutations confer severe outcome at an early age among STAT1 gain-of-function patients. Pediatr. Allergy Immunol. 33(1): e13694.
Scott O., Lindsay K., Erwood S., Mollica A., Roifman C.M., Cohn R.D., and Ivakine E.A. 2021. STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses. NPJ Genomic Med. 6(1): 34.
Toubiana J., Okada S., Hiller J., Oleastro M., Lagos Gomez M., Aldave Becerra J.C., Ouachée-Chardin M., Fouyssac F., Girisha K.M., Etzioni A., Van Montfrans J., Camcioglu Y., Kerns L.A., Belohradsky B., Blanche S., Bousfiha A., Rodriguez-Gallego C., Meyts I., Kisand K., Reichenbach J., Renner E.D., Rosenzweig S., Grimbacher B., van de Veerdonk F.L., Traidl-Hoffmann C., Picard C., Marodi L., Morio T., Kobayashi M., Lilic D., Milner J.D., Holland S., Casanova J.-L., and Puel A. 2016. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood, 127(25): 3154–3164.
Wieczorek M., Ginter T., Brand P., Heinzel T., and Krämer O.H. 2012. Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev. 23(6): 293–305.
Zhang W., Chen X., Gao G., Xing S., Zhou L., Tang X., Zhao X., and An Y. 2021. Clinical relevance of gain- and loss-of-function germline mutations in STAT1: A systematic review. Front. Immunol. 12: 654406.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 11 • Number 3 • September 2024
Pages: 67 - 72
History
Received: 19 August 2024
Accepted: 11 September 2024
Accepted manuscript online: 11 September 2024
Version of record online: 5 November 2024
Copyright
© 2024.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
AzharAl Shaqaq and Chaim M.Roifman. 2024. The outcome of haematopoietic stem cell transplantation in a patient with STAT1 gain-of-function: a case report. LymphoSign Journal.
11(3): 67-72. https://doi.org/10.14785/lymphosign-2024-0008
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Login options
Check if you access through your login credentials or your institution to get full access on this article.
